Cidara Therapeutics: Cidara granted FDA QIDP, Fast Track Designations

Cidara Therapeutics announced that the FDA has granted both Qualified Infectious Disease Product, or QIDP, and Fast Track designations for the company’s prophylaxis development program for lead antifungal product candidate, rezafungin for injection. Specifically, the QIDP designation is for the development of rezafungin for the prevention of invasive fungal infections in adults undergoing allogeneic bone marrow transplantation. Cidara previously announced QIDP designation for rezafungin for the treatment of invasive fungal infections caused by Candida.
https://thefly.com/landingPageNews.php?id=2795025